Gilead Sciences (GILD)
Salud / Biofarmacéutica
Undisputed HIV leader with Biktarvy protected by patent through 2036 (settlement agreements) and a virology/oncology pipeline that offsets the Veklury decline. At ~$148, following a re-rating from historical 'value trap' levels on normalized earnings, 5y base ~$147 (+2%/year): Preserves value — a quality business with a genuinely widening moat, at a price that already reflects much of the recent execution.
- Price
- $147.77
- Intrinsic value (5y, base)
- $147
- Total annual return (5y)
- 2.4%
- Status (nominal)
- Preserves value
- Margin of safety
- No margin
The essentials
- Undisputed HIV leader (~70% of product revenue — Biktarvy, Descovy, Yeztugo) with the sector's most extended moat: settlement agreements with Lupin, Cipla and Laurus Labs (Oct-2025) pushed Biktarvy's patent protection in the U.S. out to April 2036. Yeztugo (2025) is the only approved twice-yearly PrEP.
- GAAP is uneven due to acquired IPR&D charges: FY2024 net income collapsed to $480M on the Trodelvy NSCLC impairment ($4.2bn) and the CymaBay acquisition ($3.8bn) — an artifact of pharma M&A accounting, already normalized in the TTM ($8.8bn adjusted).
- The new structural risk: Biktarvy was selected in January 2026 for Medicare price negotiation under the IRA (negotiated price effective 2028) — the central disconfirmer of the thesis, alongside the ~70% revenue concentration in the HIV franchise.
Intrinsic value — two valuation methods
Total return at 5 years: 2.5%/year = -0.1% appreciation + 2.6% dividend. The target price ($147) is ex-dividend; the $19 in dividends collected over 5 years are added separately.
The methods disagree: one places the value today above the price ($148) and the other below.
Pillars of the analysis
The verdict — today vs 5 years
Today — expensive, no margin of safety: at $148 trades ~9.8% above its value discounted to today (~$135); the expected return does not even reach the risk-free rate (4.5%).
At 5 years — Preserva valor: the target price ($147) plus dividends yield just enough to preserve nominal capital, below the required 4% floor.
The bridge: the return at 5 years falls below the risk-free rate (4.5%) — which is why there is not even a discount to today's value. To require a 15% annual return, it would need to be bought at ~$86.
Thesis
The business
Gilead is the undisputed leader in the HIV category — treatment and prevention — with Biktarvy patent-protected through 2036 following the October 2025 settlement agreements, and Yeztugo (2025) as the market's only twice-yearly PrEP. The HIV franchise (~70% of revenue) is growing solidly (+6%) while Veklury (COVID) keeps declining and Oncology stabilizes. GAAP is uneven due to acquired IPR&D charges — FY2024 net income collapsed to $480M on the Trodelvy NSCLC impairment and the CymaBay acquisition — an accounting artifact of pharma M&A, not a deterioration of the business.
The valuation
A biopharmaceutical with predictable flows is valued on P/E over normalized net income. At ~$148 Gilead trades above normalized TTM earnings (~$8.8bn, ex the ~$450M one-time benefit from the October 2025 tax settlement) — a notable re-rating from historical single-digit 'value trap' levels; today's entry multiple isn't directly comparable, because the year-model's base year still carries non-normalized IPR&D charges, and it already sits at ~18× in 3 years. The base case projects revenue growing from its noisy trajectory average (~+3%) toward ~+4.6% by year 5, as the Veklury drag fades, with the multiple converging to a 16x exit (pharma band, mid-low tranche given IRA risk to Biktarvy). That gives ~$147/share over five years.
The margin of safety
No margin of safety: at this price capital is preserved, but it is not bought below its value. Total return combines modest price appreciation — the entry multiple's convergence toward the 16x exit absorbs much of the earnings growth (~5%/year) — with the dividend (yield ~2.5%, growing). The verdict is Preserves value: a quality business with a genuinely widening moat, but at a price that already reflects much of the recent successful execution (Yeztugo, lenacapavir, the Biktarvy patent extension), without much additional room.
What to watch
The central disconfirmer is Medicare price negotiation on Biktarvy: the negotiated price (effective 2028) will determine how much of the HIV franchise erodes through the regulatory channel, beyond patent protection. Also worth watching: the trajectory of Veklury (does it find a floor, or keep declining?), the recovery of Oncology (Trodelvy versus Cell Therapy competition), and the pipeline (bulevirtide, new lenacapavir combinations) as the replacements that sustain growth beyond Biktarvy.
Educational / informational. Does not constitute investment advice.